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The aim of the study was to analyse genes typing with the use of the oligonucleotide microarray technique (HG-U133A,
Aﬀymetrix) diﬀerentiating colorectal cancer tissues from tissues assessed histopathologically as healthy ones among a panel of
91 mRNA of genes encoding proteins involved in activation of cellular signal transduction pathways by leptin. Frozen tumor
specimens from 11 colon cancer patients in various stages of clinical progression of the disease in an I–IV stage scale according to
the TNM staging were used in molecular tests. Among the genes participating in the cascade of signal transfer in cell activated
by leptin, the following ones: AKT1, STAT3, MCL1 were qualiﬁed as diﬀerentiating stage I and II and VEGFC, CCNDI the
encoding genes respectively as diﬀerentiating III and IV stage neoplasm. It is necessary to extend studies of analysis of cellular
signal transduction pathways by leptin in colorectal cancer initiation and transformationprocesses.
1.Introduction
Leptin is a pleiotropic adipokine whose expression level and
the level of release to blood correlate to a large extent
with the amount of fat tissue in the organism. Numerous
researchers [1–5] stress the role of leptin and its receptor,
Ob-R, in induction and progression of various cancer types.
Experimentaldatarevealthatleptinmaystimulate—through
activation of cellular signal transduction pathways—cell
growth, inhibit apoptosis processes, and induce migration
processes and angiogenic factor expression in numerous
cancer types. Leptin signiﬁcantly enhanced the migratory
activity of various human colon carcinoma cell lines such
as SW480, SW620, and HCT116. The strongest eﬀect was
observed in SW480 cells, which increased their locomotor
activity from 28% spontaneously locomoting cells to 50%
[6].
The pleiotropic nature of leptin is related to presence of
the leptin receptor, Ob-R, in the organism. Several isoforms
of the leptin receptor are known. These result from alter-
native exon splicing and proteolytic protein splitting in the
already existing isoforms [7]. These are Ob-R: Ob-Ra, Ob-
Rb, Ob-Rc, Ob-Rd, and OB-Rf and the soluble form of the
Ob-Re receptor which is responsible for transport of leptin
across blood [8–10].
The aim of the study was to analyse genes typing with
the use of the oligonucleotide microarray technique (HG-
U133A, Aﬀymetrix) diﬀerentiating colorectal cancer tissues
from tissues assessed histopathologically as healthy ones
among a panel of 91 mRNA of genes encoding proteins
involved in activation of cellular signal transduction path-
ways by leptin.
2.Materialsand Method
Frozen tumorspecimens from 11 (2 coded Stage I, 2 StageII,
2 Stage III, and 2 Stage IV and 3 coded control group) colon2 ISRN Endocrinology
cancerpatientswereobtained.Allthepatientswereinformed
about the planned study, and their informed consent in
writing was obtained.
The histopathology of each specimen was reviewed to
conﬁrm diagnosis and tumor content. Tumor content was
estimated in percentage by counting nuclei of epithelial
tumor cells. Patient eligibility criteria include colon primary
stages I–IV adenocarcinoma, primary treatment is surgery
only without adjuvant or neoadjuvant therapy, at least 70%
of tumor cells in the tissue sample.
The Bioethical Commission of the Medical University of
Silesia expressed its consent to perform the tests.
2.1. Method. In the study, intraoperatively collected large
intestine specimens aﬀected by cancer of a size of 1cm3,
as well as healthy tissue specimens (margin) constituting
reference material in the study were used. Tissue material
collectedduringthesurgerywasimmediatelyplacedinsterile
tubescontaining RNA later (Sigma) in the amount of 1µLo f
tissue (200µLR N Alater per 20mg of tissue), and, following
a one-day incubation at ambient temperature, it was frozen
at −80◦C.
2.2. Microarray Analysis. The analysis of the expression pro-
ﬁle of genes coding proteins of signal cascades activated by
leptin in the samples of colorectal cancer and healthy tissue
was conducted with the oligonucleotide microarray tech-
nique with application of HG U133A plates (Aﬀymetrix).
The analysis started with comparison of the reports gener-
ated in the programme Microarray Suite Aﬀymetrix directly
after making out the ﬂuorescence signals on the microarray.
On the basis of the parameters characterizing the dis-
tribution of ﬂuorescence signals on the plate, in correspon-
dencewiththerecommendationsoftheproducerofmicroar-
rays (Aﬀymetrix “Technical Manual GeneChip Expression
Analysis”), 11 transcriptomes were accepted to the compar-
ative analysis, including 9 transcriptomes of cancer tissue
(study group) and 3 transcriptomes of healthy tissue (con-
trols). The comparative analysis of transcriptomes selected
for the tested samples started with grouping of tran-
scriptomes by data clustering (hierarchical grouping with
application of Chebyshev distance and Ward’s method),
and the conformity of grouping was assessed on the basis
of clinical, histopathological, and molecular characteristics.
The transcripts which were qualiﬁed to the same group
regardless of the applied criteria for classiﬁcation (clinical,
histopathological, or molecular) were selected to the com-
parative analysis.
In the further stage of the comparative analysis, tran-
scripts were selected from among 91 mRNA coding proteins
participating in the signal transmission pathways in cells,
activated through leptin binding to its receptor, diﬀerentiat-
ing tumour from healthy tissue.
Selection of 91 transcripts was based on data available in
the literature and the NCBI and Aﬀymetrix bases.
2.3. Statistical Analysis of the Results. The following com-
puterprogrammes were used in analysis of the data obtained
through the oligonucleotide microarray technique: Statistica
v.6.0. Microarray Suite v.5.0, SAM (signiﬁcance analysis of
microarrays), and RMA Express which enabled data normal-
ization consisting in taking logarithms of the data obtained
in the experiment.
3.Results
The comparative analysis of mRNA concentration proﬁle in
the samples of normal intestine and the samples of adeno-
carcinoma of patients with I-IV level of clinical progression
started withgrouping oftranscriptomes withWard’s method
with application of Chebyshev distance measure (i.e. the
maximum distance in any single dimension). The obtained
results indicated clear diﬀerentiation of normal transcrip-
tomesfrom samplesoflevelIandII,andIIIandIVofclinical
progression.
Taking into account various stages of clinical and patho-
logical progression of colorectal cancer in the study group,
three transcript groups were chosen for a comparative analy-
sis aimed at searching for transcripts of genes diﬀerentiating
colorectal cancer and reference tissues.
(i) Group I (4 transcriptomes) was composed of speci-
mens of carcinoma in an early stage without distant
metastases (I and II stage of clinical and pathological
cancer progression according to TNM).
(ii) Group II (3 transcriptomes) was composed of speci-
mens assessed histopathologically as control group.
(iii) Group III (4 transcriptomes) was composed of spec-
imens of carcinoma in an advanced stage collected
from patients with diagnosed regional lymph node
metastases and with distant metastases (III and IV
stage of clinical and pathological cancer progression
according to TNM).
Typing of diﬀerentiating genes was performed in a panel
of 91 transcripts of genes encoding proteins involved in
intracellular signalling activated by leptin for samples repre-
senting stages I and II (group I) and III and IV (group III) of
clinical and pathological progression of colorectal cancer as
comparedtothereference(groupII),aswellasforsamplesin
stages III and IV of colorectal cancer progression (group III)
ascomparedtosamplesrepresentingstagesIandII(groupI).
The SAM programme typed the following genes to be
statistically signiﬁcant in the compared groups as genes dif-
ferentiating stage I and II of clinical progression of colorectal
cancer: AKT1, STAT3, MCL1, and STAT5B (Table 1).
The SAM programme typed mRNA of transcripts of the
VEGFA, VEGFC, and CCND1 encoding genes to be statis-
tically signiﬁcant in the compared groups as genes diﬀeren-
tiating stages III and IV of clinical progression of colorectal
cancer (Table 2).
4.Discussion
The connection of cancer with the system of leptin and its
receptors has to be considered as a dynamic and changeable
system in relation to the external and internal environment.ISRN Endocrinology 3
Table 1: Transcripts diﬀerentiating stages I and II of colorectal cancer progression from the reference, typed from 91 transcripts by SAM.
Bold: overexpressed genes; italic: genes silenced in the group representing cancer as compared to the reference.
Early (I and II) stage of colorectal cancer progression versus reference
Genes typed by SAM
Transcript ID Gene symbol Gene name Score T Test (Q)
207163 s at AKT1 v-aktmurinethymoma viraloncogene homolog 1 3.61444 0
208991 at STAT3 signaltransducerand activator oftranscription3(acute-phase
response factor) 3.58231 0
200798 x at MCL1 myeloidcell leukemiasequence 1(BCL2-related) 3.52301 0
212549 at STAT5B signal transducer and activator of transcription 5B −5.4201 0
Table 2: Transcripts diﬀerentiating stages III and IV of colorectal cancer progression from the reference typed from 91 transcripts by SAM.
Bold: overexpressed genes; italic: genes silenced in the group representing cancer as compared to the reference.
Advanced (III and IV) stage of colorectal cancer progression versus reference
Genes typed by SAM
Transcript ID Gene symbol Gene name Score T Test (Q)
210512 s at VEGFA Vascular endothelial growth factor A −2.8837 0
209946 at VEGFC vascularendothelialgrowthfactorC 3.1135 0
208712 at CCND1 cyclinD1 2.3355 0
For instance, it is necessary to study the growth factor
receptor(s) dependency. One cannot omit the presence of
binding proteins, as well as the inﬂuence of other hormone
and growth factors and cytokines. Cancer process is a series
of molecular changes that are eﬀects of interaction of a cell
and its environment. Such processes as angiogenesis, lym-
phangiogenesis,cellmotility,proliferation,andcellapoptosis
are also important.
Authorsofnumerousarticlesattempttolinkbloodleptin
concentration with the risk of occurrence and the possibility
of transformation of various types of cancer [11–13].
Considering the therapeutic aspect, authors ask themselves
whether receptors on the surface of cancer-aﬀected cells
may be a therapeutic target for newly developed drugs, that
is, monoclonal antibodies or low-molecular-weight tyrosine
kinase inhibitors.
It was shown in the experimental part of the results
concerning the oligonucleotide microarray analysis that as
f a ra sg e n e sd i ﬀerentiating stages I–IV of clinical and patho-
logical cancer progression from the reference are concerned,
transcripts of the encoding genes AKT 1, STAT3, Mcl-
1, VEGFC, and CCND1 are expressed in cancer-aﬀected
tissues, whereas the STAT5B and VEGFA protein is silenced.
Bartucci et al. suggest that leptin activated of the ERK1/2
and AKT signaling pathways enhanced growth in soft agar
and improved sphere formation associated with E-cadherin
overexpression [14]. Hoda et al. prove that leptin may
serve as a mitogenic agent and have an antiapoptotic eﬀect
on large intestine cells [15]. Similarly, Frankenberry et al.
[11]a n dB u r g u e r ae ta l .[ 12] proved in their studies that
elevated serum leptin concentrations induce breast cancer
cell proliferation through activation of signal transduction
pathways including MAP and PI3 kinases, leading to cancer
cell growth and survival.
Ogunwobi and Beatles [16] prove in their studies of
leptin eﬀect on colorectal cancer cells that leptin stimulates
proliferation and inhibits apoptosis in human colorectal
cancer cells, involving in those processes not only PI3 kinase
but also JAK2 kinase and a transcription factor, the STAT3
protein. The STAT3 protein activates, as a transcription
factor, antiapoptotic Mc1-1 protein expression in cells. It is
postulated that elevated expression of STAT3 and its targeted
genes in colorectal carcinoma may be one of malignancy
markers. Studies conducted by Sharma et al. [4]a n dM a
et al. [17] show similarly that the endometrial cancer cell
proliferation and invasion processes are induced by leptin
which activates signal transduction pathways activating the
STAT3 protein and the ERK2 kinase.
Moreover, leptin counteracted cytotoxic eﬀects of 5-ﬂu-
orouracil, a common colon cancer therapeutic agent [14].
In the context of the obtained results, it is necessary to
extend studies of leptin and leptin receptors participation in
thecolorectalcancerinitiationandtransformation processes.
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